← Leaderboards
Min Li
Baylor College Of Medicine
$6,971,652
Attributed
$10,149,484
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $953.5K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,149,484 · 7
By mechanism
R01$9,479,626 · 5
R21$366,850 · 1
P30$303,008 · 1
Top collaborators
- Yi-Ping Li6 shared
- Martin Ernesto Fernandez-Zapico5 shared
- Wei R. Chen4 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Amit Joshi$4,022,481
- Zhaoyong Hu$3,424,065
- Jin Wang$27,891,294
- Janel Ann Merkel Peterson$148,642
Others in their field
Top investigators on “Malignant Neoplasm Of Pancreas”
- David Heimbrook · Leidos Biomedical Research, Inc.$73,277,592
- Anirban Maitra · Johns Hopkins University$43,028,398
- Walter John Curran · Thomas Jefferson University$26,641,549
- Surinder Kumar Batra · University Of Pittsburgh At Pittsburgh$26,074,679
- Michael A Hollingsworth · University Of Nebraska Medical Center$23,837,917
- Robert E Reiter · University Of California Los Angeles$21,473,394
Research focus
Malignant Neoplasm Of PancreasMalignant NeoplasmsTumor GrowthGrowthZinc-Binding ProteinXenograft ProcedurePathway InteractionsMouse ModelEffective TherapyTherapeutic TargetOverexpressionMediatingFoundationsCellsDiagnosisSurvival RateNew Therapeutic TargetTumorPancreatic Cancer CellsTumor ProgressionCancer CenterNeoplastic CellGenetic TranscriptionOncogenic
Grant awards (35)
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors$489,114
R01 · FY2025 · CA
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors$465,002
R01 · FY2024 · CA
Role of Zinc Dependent EMT-Transcription Factors (EMT-TF) in Pancreatic Cancer Metastasis$315,104
R01 · FY2024 · CA · contact PI
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors$476,752
R01 · FY2023 · CA
Role of Zinc Dependent EMT-Transcription Factors (EMT-TF) in Pancreatic Cancer Metastasis$325,054
R01 · FY2023 · CA · contact PI
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors$535,638
R01 · FY2022 · CA
Role of Zinc Dependent EMT-Transcription Factors (EMT-TF) in Pancreatic Cancer Metastasis$325,054
R01 · FY2022 · CA · contact PI
Preclinical Translational Cancer Research Program$53,817
P30 · FY2022 · CA · contact PI
Role of Zinc Dependent EMT-Transcription Factors (EMT-TF) in Pancreatic Cancer Metastasis$331,688
R01 · FY2021 · CA · contact PI
Preclinical Translational Cancer Research Program$53,817
P30 · FY2021 · CA · contact PI
Prognostic Biomarkers for ZIP4-mediated Cachexia in Pancreatic Cancer$517,047
R01 · FY2020 · CA · contact PI
Role of Zinc Dependent EMT-Transcription Factors (EMT-TF) in Pancreatic Cancer Metastasis$331,688
R01 · FY2020 · CA · contact PI
Preclinical Translational Cancer Research Program$53,817
P30 · FY2020 · CA · contact PI
Prognostic Biomarkers for ZIP4-mediated Cachexia in Pancreatic Cancer$505,431
R01 · FY2019 · CA · contact PI
ZIP4 is a Novel Molecular Target in Human Pancreatic Cancer$332,649
R01 · FY2019 · CA · contact PI
Preclinical Translational Cancer Research Program$56,592
P30 · FY2019 · CA · contact PI
Prognostic Biomarkers for ZIP4-mediated Cachexia in Pancreatic Cancer$525,645
R01 · FY2018 · CA · contact PI
ZIP4 is a Novel Molecular Target in Human Pancreatic Cancer$342,938
R01 · FY2018 · CA · contact PI
Preclinical Translational Cancer Research Program$53,817
P30 · FY2018 · CA · contact PI
Preclinical Translational Cancer Research Program$21,409
P30 · FY2018 · CA · contact PI
Preclinical Translational Cancer Research Program$9,739
P30 · FY2018 · CA · contact PI
Prognostic Biomarkers for ZIP4-mediated Cachexia in Pancreatic Cancer$539,228
R01 · FY2017 · CA · contact PI
ZIP4 is a Novel Molecular Target in Human Pancreatic Cancer$342,938
R01 · FY2017 · CA · contact PI
Prognostic Biomarkers for ZIP4-mediated Cachexia in Pancreatic Cancer$464,105
R01 · FY2016 · CA · contact PI
ZIP4 is a Novel Molecular Target in Human Pancreatic Cancer$347,191
R01 · FY2016 · CA · contact PI
Prognostic Biomarkers for ZIP4-mediated Cachexia in Pancreatic Cancer$109,301
R01 · FY2016 · CA · contact PI
ZIP4 is a Novel Molecular Target in Human Pancreatic Cancer$362,685
R01 · FY2015 · CA · contact PI
Role of Dietary Zinc Transporter ZIP4 in Pancreatic Cancer$289,859
R01 · FY2015 · CA · contact PI
Role of Dietary Zinc Transporter ZIP4 in Pancreatic Cancer$283,175
R01 · FY2014 · CA · contact PI
Role of Dietary Zinc Transporter ZIP4 in Pancreatic Cancer$1
R01 · FY2013 · CA · contact PI
Role of Dietary Zinc Transporter ZIP4 in Pancreatic Cancer$301,913
R01 · FY2012 · CA · contact PI
Role of Dietary Zinc Transporter ZIP4 in Pancreatic Cancer$301,913
R01 · FY2011 · CA · contact PI
Role of Dietary Zinc Transporter ZIP4 in Pancreatic Cancer$318,513
R01 · FY2010 · CA · contact PI
Roles of Zinc Transporter ZIP4 (SLC39A4) in Pancreatic Cancer Pathogenesis$198,000
R21 · FY2010 · CA · contact PI
Roles of Zinc Transporter ZIP4 (SLC39A4) in Pancreatic Cancer Pathogenesis$168,850
R21 · FY2009 · CA · contact PI